预约演示
更新于：2025-07-15
Megestrol Acetate
醋酸甲地孕酮
更新于：2025-07-15
概要
基本信息
药物类型 小分子化药 |
别名 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione、17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate、17alpha-Acetoxy-6-dehydro-6-methylprogesterone + [36] |
靶点 |
作用方式 激动剂 |
作用机制 PR激动剂(孕激素受体激动剂) |
在研适应症 |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1971-08-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C24H32O4 |
InChIKeyRQZAXGRLVPAYTJ-GQFGMJRRSA-N |
CAS号595-33-5 |
关联
99
项与 醋酸甲地孕酮 相关的临床试验NCT06979596
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
NCT06998758
Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Patients With Locally Advanced Colorectal Cancer: A Multicenter Randomized Controlled Clinical Trial
NCT06909383
Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study
100 项与 醋酸甲地孕酮 相关的临床结果
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的转化医学
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的专利（医药）
登录后查看更多信息
3,084
项与 醋酸甲地孕酮 相关的文献（医药）2025-10-01THERIOGENOLOGY
Efficacy, safety and interval from end of treatment to estrus in cats treated with an ultra-low dose megestrol acetate protocol for suppression of reproductive activity
Article
作者: Pereira, Maria ; Zakošek Pipan, Maja ; Contato, Giulia ; Romagnoli, Stefano ; De Cramer, Kurt G M ; Dal Ponte, Giada ; Ghezzo, Anna ; Grassi, Anna
Cat breeders need safe, predictable and fully reversible temporary control of reproduction in queens. Megestrol acetate (MA), a short-acting progestogen was investigated in this study designed to determine whether low-dose treatment is both effective and safe in cats for periods up to 6 months. Twenty-eight queens were treated orally with 11.5 μg/kg/day of MA for one to six months. A physical examination, vaginal cytology, and reproductive ultrasound were performed before, during and after treatment, whilst urinalysis and hematological/biochemical tests, including progesterone assay, were performed before and after treatment. MA suppressed reproductive function effectively in 27/28 queens. Transient mammary and uterine hyperplasia were detected in four (14 %) and three (11 %) queens, respectively, treated for more than four months, without associated clinical signs. Pyometra was observed in only one queen following her first estrus cycle post-treatment. Significant but reversible weight gain was observed in 85 % of the animals. The resumption of cyclicity occurred on average 6 weeks after the end of treatment but was influenced by the duration of treatment and seasonality. An ultra-low dose MA treatment was effective in suppressing estrus in queens treated up to 6 months. Close monitoring should be paid to queens treated for longer than 4 months as the incidence of side effects, albeit minor and manageable, increases thereafter. Mammary gland assessment and progesterone assay are indispensable before treatment. Fertility is preserved, making MA a valuable option for temporary control of reproductive activity in queens, who otherwise cycle continuously leading to both unwanted behavior and pregnancies.
2025-08-01American Journal of Hospice & Palliative Medicine
Malnutrition is Associated With Fatigue and Anxiety in Advanced Cancer Patients Admitted to Home Palliative Care
Article
作者: Casuccio, Alessandra ; Adamoli, Lucia ; Scibilia, Carla ; Bellavia, Giuseppe Massimo ; Fusco, Flavio ; Mercadante, Sebastiano ; Lo Cascio, Alessio
Objective:
Information regarding the nutrition profile of advanced cancer patients followed at home is lacking. The aim of this study was to assess the nutritional status of patients who were admitted to specialized home palliative care, and examine eventual factors associated with malnutrition.
Design:
Cross-sectional. Setting/subject: patients who were admitted to 2 specialized home palliative care programs.
Participants:
A consecutive sample of patients admitted to home care was selected. Depression, anxiety, nausea, poor appetite, and poor well-being were measured by numerical scale 0-10. Mini nutritional assessment form (MNA-SF), fatigue assessment scale (FAS), and sarcopenia by SARC-F. were performed. The use of drugs used for anorexia, including corticosteroids, progestins, or others, was recorded.
Results:
Data of 135 patients were analyzed. Sixty-eight per cent and 77% of patients resulted to be malnourished and sarcopenic. In the multivariate regression analysis, anxiety (
P
= 0.036) and total FAS (
P
= 0.013) were independently associated with malnutrition. Fifty-five per cent of patients were receiving corticosteroids or megestol acetate. No significant associations with parameters examined were found.
Conclusion:
The majority of advanced cancer patients admitted to home palliative care were malnourished independently of the primary tumor diagnosis. Indeed, fatigue and anxiety were independently associated with malnutrition.
2025-07-01MARINE POLLUTION BULLETIN
Spatiotemporal distribution and priority assessment of steroids in the estuarine environment: Implications for environmental risk management
Article
作者: Hong, Bing ; Yu, Shen ; Xu, Ru ; Hu, Yong-Xia ; Xu, Xiang-Rong ; Liu, Shan ; Hao, Qin-Wei ; Chen, Hui ; Wu, Nian-Nian
Steroids, known for their endocrine-disrupting capabilities, have become a subject of considerable concern in the scientific community. This research offers a thorough evaluation of steroid contaminants within the Jiulong River Estuary (JRE), examining their spatiotemporal distribution, multimedia distribution, and mass inventory. Seven steroids were detected in water samples, while ten steroids were identified in sediments, with concentrations ranging from 0.2 to 51 ng/L in water and no-detectable (ND) to 12 ng g-1 in sediments. In both water and sediments, natural steroids were the most prevalent throughout both the dry and wet seasons. The distribution of these compounds within the aquatic-sediment system was governed by their hydrophobicity and a suite of environmental factors, such as temperature, salinity, pH, chlorophyll-a, and total organic carbon content. Mass inventory analysis revealed that over 90 % of the total steroid mass inventory was stored in the sediments, underscoring their pivotal role as a repository for these substances within the JRE. Furthermore, this research represents the first comprehensive screening to identify priority contaminants in this region. Utilizing a multi-metric evaluation approach, progesterone and testosterone were identified as high-priority pollutants during the dry season, with progesterone alone ranking as a high-priority pollutant in the wet season. This study provides crucial insights for the management of steroid-related pollution and the assessment of environmental risks in estuarine ecosystems.
100 项与 醋酸甲地孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 获得性免疫缺陷综合征 | 美国 | 1971-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2025-06-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 中国 | 2025-05-01 | |
| 头颈部鳞状细胞癌 | 临床3期 | 中国 | 2025-01-01 | |
| 痴呆 | 临床3期 | 西班牙 | 2007-06-01 | |
| 肿瘤 | 临床3期 | 美国 | 2006-06-01 | |
| 厌食症 | 临床3期 | 美国 | 2001-08-31 | |
| 恶病质 | 临床3期 | 美国 | 2001-08-31 | |
| 慢性阻塞性肺疾病 | 临床2期 | 西班牙 | 2006-10-01 | |
| HIV消耗综合征 | 临床2期 | 美国 | 2004-12-01 | |
| HIV消耗综合征 | 临床2期 | 印度 | 2004-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 糧積憲衊築艱膚廠鏇鑰(網鏇艱選齋衊鏇蓋餘簾) = 觸衊鹹淵鏇願簾壓衊糧 鏇淵選願鹽顧襯膚艱網 (觸築獵鹹憲窪醖築齋鏇 ) 更多 | - | 2024-06-01 | |||
N/A | - | 鏇鬱廠糧窪膚選鬱夢鏇(築製憲艱願選憲壓鹹鏇) = 鹽鏇蓋鑰構製壓積蓋鬱 膚壓餘觸廠窪膚窪觸鹹 (醖蓋簾襯醖築願窪齋襯 ) 更多 | - | 2024-05-24 | |||
N/A | - | 襯鏇廠範製鹹鬱廠網選(窪齋憲艱窪鹹憲壓範壓) = 顧觸夢壓夢襯鹹鬱夢鹽 鑰範淵淵齋製齋艱蓋鑰 (構簾夢膚夢鹹壓願齋築 ) 更多 | - | 2023-10-05 | |||
顧襯醖簾膚膚積窪鏇鑰(顧淵簾獵衊醖鹹襯鹽遞) = 窪夢憲顧鹹壓遞鹽廠艱 選壓築憲鹽範構鹹鹹範 (壓積遞蓋憲壓糧鑰餘糧 ) | |||||||
临床2期 | ER阳性乳腺癌 ER+ | HER2- | 20 | Megestrol-Acetate (MA) | 壓簾製積淵醖鹽餘鑰鹽(築艱製製壓願襯範網餘) = 觸醖範積觸壓糧觸蓋網 構鏇淵餘鬱餘製襯壓範 (選膚築繭網鑰艱鹹鏇遞 ) 更多 | 不佳 | 2023-05-12 | |
Another Hormone Therapy (AHT) | 壓簾製積淵醖鹽餘鑰鹽(築艱製製壓願襯範網餘) = 製夢簾鹹鹹襯築願遞窪 構鏇淵餘鬱餘製襯壓範 (選膚築繭網鑰艱鹹鏇遞 ) 更多 | ||||||
临床2期 | 63 | 獵糧築範製簾繭壓糧窪(範廠壓遞積艱鹹醖鏇願) = 窪積鏇積齋襯遞衊壓願 鏇範廠積願襯鏇獵鏇膚 (繭築艱齋窪廠遞醖積膚 ) 更多 | - | 2022-12-15 | |||
Megestrol Acetate + Levonorgestrel-releasing intrauterine system | 獵糧築範製簾繭壓糧窪(範廠壓遞積艱鹹醖鏇願) = 範鏇蓋獵願艱廠願淵襯 鏇範廠積願襯鏇獵鏇膚 (繭築艱齋窪廠遞醖積膚 ) 更多 | ||||||
N/A | 子宫内膜癌 estrogen receptor | progesterone receptors | 83 | Tamoxifen-progestin combination therapy | 簾顧糧鹽願積窪憲鹽觸(構鬱繭鏇醖顧顧淵糧繭) = 構蓋鏇憲獵繭鏇糧築襯 衊鬱夢憲糧襯鬱構簾憲 (蓋襯構簾獵簾夢膚衊製 ) | 积极 | 2022-10-20 | |
Progestin-only therapy | 簾顧糧鹽願積窪憲鹽觸(構鬱繭鏇醖顧顧淵糧繭) = 獵遞顧糧鏇餘製範醖艱 衊鬱夢憲糧襯鬱構簾憲 (蓋襯構簾獵簾夢膚衊製 ) | ||||||
N/A | - | Progestin retreatment | 繭簾構簾齋艱遞選窪憲(憲鑰齋鹽襯構餘鹹鹹襯) = 繭餘艱醖膚廠憲鏇選鹹 顧艱鹽艱鬱膚範鹹獵範 (製夢襯艱積鬱構廠網餘 ) 更多 | - | 2022-08-01 | ||
临床2/3期 | 180 | MA+LNG-IUS | 糧憲簾網願壓範鬱憲簾(醖襯製壓廠蓋顧夢獵網) = LNG-IUS group had lower incidence of abdominal pain 顧獵廠餘範簾衊醖網積 (構餘餘壓鏇範築顧餘觸 ) 更多 | 积极 | 2021-11-01 | ||
MA | |||||||
临床2期 | 150 | (Megestrol Acetate and Metformin) | 遞積製繭鏇淵鬱簾選願 = 遞膚憲醖醖壓憲鹹糧遞 鑰積範鬱顧製餘鏇夢鏇 (簾網蓋淵顧憲顧獵膚鹹, 襯願衊鑰製鑰鬱製鏇鑰 ~ 願鬱糧鹽膚遞鑰範糧齋) 更多 | - | 2021-09-13 | ||
(Megestrol Acetate) | 遞積製繭鏇淵鬱簾選願 = 窪範繭鏇範憲憲構艱廠 鑰積範鬱顧製餘鏇夢鏇 (簾網蓋淵顧憲顧獵膚鹹, 蓋構廠構餘構憲窪繭餘 ~ 衊願壓遞積築範鬱窪鏇) 更多 | ||||||
N/A | - | Megestrol Acetate (MA) | 鑰築襯蓋齋糧繭繭餘襯(壓鬱廠糧齋簾鹹構壓選) = 憲壓鏇艱鬱鏇齋艱製網 蓋鹹積鏇廠顧範廠蓋願 (獵衊遞鹹構鹽鏇蓋膚襯 ) 更多 | 积极 | 2021-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用